Cardiology Department, Wroclaw Medical University, Wroclaw, Poland; Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia; Baker Heart and Diabetes Institute, Melbourne, Australia.
Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia; Baker Heart and Diabetes Institute, Melbourne, Australia.
JACC Cardiovasc Imaging. 2020 Jan;13(1 Pt 2):215-227. doi: 10.1016/j.jcmg.2018.10.039. Epub 2019 Apr 17.
Asymptomatic left ventricular diastolic dysfunction (ALVDD) (diastolic abnormalities and normal ejection fraction in the absence of symptoms) is associated with incident heart failure (HF) and decreased survival. Abnormalities of diastolic function might therefore be included in the definition of stage B HF, which denotes individuals at risk for the development of HF. Imaging techniques, especially echocardiography, are necessary for the recognition of preclinical left ventricular (LV) diastolic disturbances, as well as further tracking of pathological changes and responses to treatment. The transition of ALVDD to symptomatic HF is underlain by multiple factors, including both cardiovascular and noncardiovascular determinants. The initiation of management strategies targeting cardiovascular and systemic comorbidities in patients identified as having ALVDD may delay symptomatic progression and improve prognosis.
无症状性左心室舒张功能障碍(ALVDD)(无症状时舒张异常和正常射血分数)与心力衰竭(HF)事件和生存率降低相关。因此,舒张功能异常可能被纳入 HF 阶段 B 的定义中,该定义表示存在 HF 发展风险的个体。影像学技术,尤其是超声心动图,对于识别临床前左心室(LV)舒张功能障碍以及进一步跟踪病理性改变和对治疗的反应是必要的。无症状性 HF 从 ALVDD 发展而来的基础是多种因素,包括心血管和非心血管决定因素。针对被识别为存在 ALVDD 的患者的心血管和系统性合并症启动管理策略可能会延迟症状进展并改善预后。